导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 11.13% | 781/4773 |
| 近一周 | -0.58% | 1149/5465 |
| 近一月 | -7.63% | 4627/5421 |
| 近一季 | -10.23% | 3723/5231 |
| 近半年 | 8.16% | 664/4920 |
| 近一年 | 12.58% | 943/4394 |
| 近两年 | 91.51% | 709/2954 |
| 近三年 | 48.74% | 586/2253 |
| 成立以来 | 91.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.93% 2971/4961 |
43.02% 718/5312 |
- - |
- - |
| 2025 | 36.62% 937/4813 |
3.95% 1014/3635 |
1.36% 2365/4076 |
34.46% 1013/4524 |
-3.57% 3294/4813 |
| 2024 | 3.81% 1908/3463 |
-5.67% 1940/2808 |
-5.13% 1658/3014 |
15.19% 1791/3129 |
0.70% 1178/3463 |
| 2023 | -8.80% 1059/2656 |
12.62% 287/2280 |
-3.94% 978/2385 |
-10.71% 2016/2515 |
-5.59% 1406/2655 |
| 2022 | -25.25% 1300/2207 |
-18.79% 1397/1919 |
4.69% 981/2016 |
-15.86% 1357/2113 |
4.49% 542/2208 |
| 2021 | 12.89% 370/1822 |
-5.61% 939/1255 |
19.59% 159/1330 |
-5.71% 846/1466 |
6.06% 243/1822 |
| 2020 | 71.07% 66/1250 |
4.53% 71/1028 |
23.58% 191/1067 |
12.14% 404/1164 |
18.10% 104/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 申万菱信中证研发创新100ETF联接C VS. 长安沪深300非周期A(740101) |